Pharmaceutical & BioTech

Health Economic (HE) Models play a pivotal role in the ever-evolving landscape of pharmaceutical Pricing & Reimbursement (P&R).

With economic evaluations gaining prominence in negotiations with the local Agency, RPN specializes in developing and adapting HE Models tailored to the local environment and their seamless integration within the product Dossier.

We collaborate closely with key opinion leaders (KOLs) to identify comparators and local treatment pathways, collect relevant unit costs aligned with the perspective of the local NHS, and conduct rigorous sensitivity analyses.

Budget Impact Models (BIM) and Cost Effectiveness Models (CEM) play a decisive role in the reimbursement process. These models serve as crucial tools for payers and decision makers, evaluating the financial feasibility of new health technologies and demonstrating cost-effectiveness to payers. A meticulous process of country adaptation not only minimizes discrepancies in economic analyses but also expedites the HTA process, paving the way for efficient market access.

Model adaptation will entail:

• Identification of key comparators, local treatment processes, and local resource consumption.
• Identification and collection of unit costs (consistent with the perspective of the NHS).
• Production of final results and sensitivity analyses.
• Inclusion of the results (for both BIM and CEM) in the P&R Dossier.